Hobart Private Capital LLC Boosts Stock Position in Eli Lilly and Company $LLY

Hobart Private Capital LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 25.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,180 shares of the company’s stock after acquiring an additional 443 shares during the period. Hobart Private Capital LLC’s holdings in Eli Lilly and Company were worth $1,699,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter worth $27,000. Blume Capital Management Inc. raised its position in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares in the last quarter. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares in the last quarter. Finally, IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter worth $35,000. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Daniel Skovronsky acquired 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on LLY shares. BMO Capital Markets increased their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. JPMorgan Chase & Co. lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $938.61.

Eli Lilly and Company Stock Up 0.6%

LLY opened at $825.86 on Friday. The company has a market cap of $781.65 billion, a P/E ratio of 53.98, a P/E/G ratio of 1.18 and a beta of 0.47. The business’s 50-day moving average price is $768.01 and its 200-day moving average price is $768.14. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.